New clinical studies used molecular and imaging-linked biomarkers to flag relapse risk earlier in several cancers. A retrospective breast cancer analysis tied PET/CT metabolic measures obtained before surgery to recurrence or metastasis within 24 months, while prostate-cancer work connected radiogenomic and RNA signatures to prognosis. For clinicians, these results add to a growing toolset aimed at tightening risk stratification using pre-treatment or peri-operative data. The immediate value is in supporting more informed surveillance and treatment intensity decisions, particularly where standard staging can fail to capture biological aggressiveness. However, multiple studies were retrospective or single-center and emphasized the need for external validation. The next step for the field is demonstrating consistent performance across scanners, cohorts, and treatment protocols, and determining whether acting on these risk signals improves outcomes. Taken together, the work underscores continued momentum behind imaging-derived quantification and bioinformatic signatures as practical levers for precision oncology—pending prospective confirmation.